Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock in an open-market transaction. The sale occurred on June 1, 2026 at a weighted average price of $9.24 per share, with individual trade prices ranging from $9.15 to $9.62 per share.
After this transaction, Sarchi directly holds 180,962 Replimune shares. The filing notes that the sale was executed under a pre-arranged trading plan adopted on December 15, 2025 intended to comply with Rule 10b5-1(c), indicating it was scheduled in advance rather than timed discretionarily.
Replimune Group, Inc. announced that, after collaborative discussions with the U.S. Food and Drug Administration, it plans to resubmit its Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
The FDA has indicated it will treat the resubmission as an urgent matter and prioritize its review, reflecting the unmet medical need for patients whose disease has progressed after prior anti‑PD‑1 therapy. The BLA is supported by data from the IGNYTE clinical trial of RP1 plus nivolumab in this difficult-to-treat population.
Replimune highlights that melanoma is the fifth most common cancer in the U.S. and the most lethal form of skin cancer, with many patients not responding to current immune checkpoint therapies, underscoring the rationale for developing RP1.
Replimune Group, Inc. Schedule 13G reports that Ridgeback entities beneficially own 6,252,651 shares of common stock, representing 7.6% of the class based on January 30, 2026 outstanding share count. The reporting group is Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC.
The filing states that the shared voting and dispositive power over these shares is 6,252,651 and that RCI and RCM may be deemed to beneficially own all shares by Rule 13d-3; each disclaims ownership except to the extent of any pecuniary interest. Signatures by counsel are dated 05/21/2026.
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported an open-market sale of 14,023 shares of common stock on May 18, 2026 at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations from the partial vesting of his Restricted Stock Units under an irrevocable “sell to cover” provision, meaning the transaction was not a discretionary sale. After this tax-related sale, he continues to hold 235,662 shares directly.
Replimune Group, Inc. Chief Accounting Officer Andrew Schwendenman reported an open-market sale of 7,894 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations arising from a partial vesting of his Restricted Stock Units under a pre-set “sell to cover” provision, rather than a discretionary sale. Following this transaction, he directly holds 107,057 shares of Replimune common stock.
Replimune Group, Inc.’s Chief Commercial Officer Christopher Sarchi reported an open-market sale of 8,626 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to a partial vesting of his restricted stock units under an irrevocable “sell to cover” provision, meaning the transaction was not a discretionary sale. After this tax-related sale, Sarchi directly holds 192,962 shares of Replimune common stock.
Replimune Group, Inc. director Philip Astley-Sparke reported an open-market sale of 17,657 shares of common stock at a weighted average price of $5.08 per share. The shares were sold under an irrevocable “sell to cover” provision to satisfy tax withholding on partially vesting RSUs and are described as non-discretionary.
The filing notes the trades occurred at prices ranging from $5.02 to $5.08 per share. Following this tax-related sale, Astley-Sparke directly holds 1,412,414 shares of Replimune common stock.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported selling 37,324 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations from the partial vesting of his Restricted Stock Units.
The sales occurred in multiple transactions at prices ranging from $5.01 to $5.08 per share under an irrevocable “sell to cover” provision in the RSU award agreements, described as non-discretionary. Following these transactions, Patel directly holds 747,492 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported an open-market sale of 7,812 shares of common stock. The shares were sold at a weighted average price of $5.08 per share to cover tax withholding obligations tied to the partial vesting of her Restricted Stock Units.
The sale was executed under an irrevocable “sell to cover” provision in the RSU award agreements and is described as not representing a discretionary sale by the reporting person. After these transactions, she directly holds 236,556 shares of Replimune common stock.
Replimune Group, Inc. ownership update: RTW Investments, LP and Roderick Wong report beneficial ownership of 7,356,916 shares, representing 8.9% of the class. The filing cites 82,572,619 Shares outstanding as of January 30, 2026. The Reporting Persons disclose shared voting and shared dispositive power over those shares.